Literature DB >> 33862292

Insight into the drug resistance whole genome of Mycobacterium tuberculosis isolates from Khyber Pakhtunkhwa, Pakistan.

Muhammad Tahir Khan1, Sajid Ali2, Anwar Sheed Khan3, Arif Ali4, Abbas Khan5, Aman Chandra Kaushik6, Muhammad Irfan7, Sathishkumar Chinnasamy8, Shulin Zhang9, Yu-Juan Zhang10, Zhilei Cui11, Amie Jinghua Wei8, Yanjie Wang8, Mingzhu Zhao12, Kejia Liu13, Heng Wang14, Muhammad Tariq Zeb15, Dong Qing Wei16.   

Abstract

Whole genome sequencing (WGS) is one of the most reliable methods for detection of drug resistance, genetic diversity in other virulence factor and also evolutionary dynamics of Mycobacterium tuberculosis complex (MTBC). First-line anti-tuberculosis drugs are the major weapons against Mycobacterium tuberculosis (MTB). However, the emergence of drug resistance remained a major obstacle towards global tuberculosis (TB) control program 2030, especially in high burden countries including Pakistan. To overcome the resistance and design potent drugs, genomic variations in drugs targets as well as in the virulence and evolutionary factors might be useful for better understanding and designing potential inhibitors. Here we aimed to find genomic variations in the first-line drugs targets, along with other virulence and evolutionary factors among the circulating isolates in Khyber Pakhtunkhwa, Pakistan. Samples were collected and drug susceptibility testing (DST) was performed as per WHO standard. The resistance samples were subjected to WGS. Among the five whole genome sequences, three samples (NCBI BioProject Accession: PRJNA629298, PRJNA629388) harbored 1997, 1162, and 2053 mutations. Some novel mutations have been detected in drugs targets. Similarly, numerous novel variants have also been detected in virulency and evolutionary factors, PE, PPE, and secretory system of MTB isolates. Exploring the genomic variations among the circulating isolates in geographical specific locations might be useful for future drug designing. To the best of our knowledge, this is the first study that provides useful data regarding the insight genomic variations in virulency, evolutionary factors including ESX and PE/PPE as well as drug targets, for better understanding and management of TB in a WHO declared high burden country.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Genome; PE; PPE; PZA; Resistance

Mesh:

Year:  2021        PMID: 33862292     DOI: 10.1016/j.meegid.2021.104861

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  4 in total

1.  Novel Mutations in Putative Nicotinic Acid Phosphoribosyltransferases of Mycobacterium tuberculosis and Their Effect on Protein Thermodynamic Properties.

Authors:  Yu-Juan Zhang; Muhammad Tahir Khan; Madeeha Shahzad Lodhi; Hadba Al-Amrah; Salma Saleh Alrdahe; Hanan Ali Alatawi; Doaa Bahaa Eldin Darwish
Journal:  Polymers (Basel)       Date:  2022-04-18       Impact factor: 4.967

2.  Drug Resistance Patterns and Trends in Patients with Suspected Drug-Resistant Tuberculosis in Dalian, China: A Retrospective Study.

Authors:  Yuanping Pan; Yingying Yu; Jiachen Lu; Yaohui Yi; Xiaofeng Dou; Ling Zhou
Journal:  Infect Drug Resist       Date:  2022-07-30       Impact factor: 4.177

3.  Insights Into Mutations Induced Conformational Changes and Rearrangement of Fe2+ Ion in pncA Gene of Mycobacterium tuberculosis to Decipher the Mechanism of Resistance to Pyrazinamide.

Authors:  Asma Sindhoo Nangraj; Abbas Khan; Shaheena Umbreen; Sana Sahar; Maryam Arshad; Saba Younas; Sajjad Ahmad; Shahid Ali; Syed Shujait Ali; Liaqat Ali; Dong-Qing Wei
Journal:  Front Mol Biosci       Date:  2021-05-20

4.  Characterization of rifampicin-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan.

Authors:  Anwar Sheed Khan; Jody E Phelan; Muhammad Tahir Khan; Sajid Ali; Muhammad Qasim; Gary Napier; Susana Campino; Sajjad Ahmad; Otavio Marques Cabral; Shulin Zhang; Hazir Rahman; Dong-Qing Wei; Taane G Clark; Taj Ali Khan
Journal:  Sci Rep       Date:  2021-07-09       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.